Christian Manegold

21.8k total citations · 8 hit papers
113 papers, 16.2k citations indexed

About

Christian Manegold is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Christian Manegold has authored 113 papers receiving a total of 16.2k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Pulmonary and Respiratory Medicine, 63 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Christian Manegold's work include Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (35 papers) and Lung Cancer Diagnosis and Treatment (30 papers). Christian Manegold is often cited by papers focused on Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (35 papers) and Lung Cancer Diagnosis and Treatment (30 papers). Christian Manegold collaborates with scholars based in Germany, United States and Italy. Christian Manegold's co-authors include U. Gatzemeier, Joachim von Pawel, Giorgio V. Scagliotti, Paolo Paoletti, Giuseppe Giaccone, Filippo de Marinis, James J. Rusthoven, James T. Symanowski, E. Kaukel and Michael Boyer and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Christian Manegold

111 papers receiving 15.7k citations

Hit Papers

Phase III Study Comparing... 2003 2026 2010 2018 2008 2003 2004 2004 2004 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
    2008 2.5k citations Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology profile →
  2. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
    2003 2.3k citations Nicholas J. Vogelzang, James J. Rusthoven et al. Journal of Clinical Oncology profile →
  3. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
    2004 1.9k citations Nasser H. Hanna, Frances A. Shepherd et al. Journal of Clinical Oncology profile →
  4. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
    2004 1.4k citations Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology profile →
  5. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
    2004 1.4k citations Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology profile →
  6. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
    2009 1.2k citations Martin Reck, Joachim von Pawel et al. Journal of Clinical Oncology profile →
  7. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
    2005 518 citations Daphne W. Bell, Thomas J. Lynch et al. Journal of Clinical Oncology profile →
  8. Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
    2005 474 citations Christian Manegold, Giuseppe Giaccone et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christian Manegold Germany 39 13.0k 9.4k 3.2k 1.9k 1.1k 113 16.2k
U. Gatzemeier Germany 42 12.3k 0.9× 10.7k 1.1× 3.6k 1.1× 1.8k 0.9× 764 0.7× 184 16.3k
Rodryg Ramlau Poland 43 9.1k 0.7× 8.9k 0.9× 3.1k 1.0× 1.6k 0.8× 547 0.5× 245 12.8k
Vera Hirsh Canada 52 14.2k 1.1× 14.7k 1.6× 4.9k 1.5× 2.8k 1.5× 1.5k 1.3× 197 19.7k
Filippo de Marinis Italy 52 14.8k 1.1× 13.4k 1.4× 4.0k 1.3× 2.7k 1.4× 930 0.8× 450 19.0k
Maciej Krzakowski Poland 43 6.4k 0.5× 7.6k 0.8× 2.2k 0.7× 1.6k 0.8× 785 0.7× 261 11.4k
Isamu Okamoto Japan 61 9.4k 0.7× 9.5k 1.0× 4.1k 1.3× 2.0k 1.1× 596 0.5× 383 13.9k
Camelia S. Sima United States 60 9.4k 0.7× 6.3k 0.7× 2.7k 0.9× 2.0k 1.1× 1.4k 1.2× 169 13.3k
Frank V. Fossella United States 47 9.1k 0.7× 8.6k 0.9× 2.5k 0.8× 1.1k 0.5× 833 0.7× 197 12.8k
Nobuyuki Yamamoto Japan 58 12.5k 1.0× 11.6k 1.2× 4.0k 1.3× 2.5k 1.3× 736 0.6× 574 17.3k
Tudor–Eliade Ciuleanu Romania 47 11.7k 0.9× 12.7k 1.4× 3.9k 1.2× 2.7k 1.4× 808 0.7× 202 17.3k

Countries citing papers authored by Christian Manegold

Since Specialization
Citations

This map shows the geographic impact of Christian Manegold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Manegold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Manegold more than expected).

Fields of papers citing papers by Christian Manegold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christian Manegold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Manegold. The network helps show where Christian Manegold may publish in the future.

Co-authorship network of co-authors of Christian Manegold

This figure shows the co-authorship network connecting the top 25 collaborators of Christian Manegold. A scholar is included among the top collaborators of Christian Manegold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christian Manegold. Christian Manegold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sulewska, Anetta, Lothar R. Pilz, Christian Manegold, et al.. (2023). A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives. Cells. 12(6). 905–905. 11 indexed citations
2.
Vogelzang, Nicholas J., James J. Rusthoven, James T. Symanowski, et al.. (2023). Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 41(12). 2125–2133. 18 indexed citations
3.
Su, Chunxia, Mathias Meyer, Robert Pirker, et al.. (2016). From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel. Translational Lung Cancer Research. 5(4). 377–388. 2 indexed citations
4.
Huber, Rudolf M., Michael Flentje, Jochen Willner, et al.. (2010). Concurrent Chemoradiation Therapy With Docetaxel/Cisplatin Followed by Docetaxel Consolidation Therapy in Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer: Results of a Phase I Study. Clinical Lung Cancer. 11(1). 45–50. 4 indexed citations
5.
Nikolova, Dessislava A., Irfan A. Asangani, Laura D. Nelson, et al.. (2009). Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity. Cancer Research. 69(6). 2461–2470. 23 indexed citations
6.
Manegold, Christian, Johan Vansteenkiste, Felipe Cardenal, et al.. (2009). A randomized, parallel-group, phase II study to evaluate the efficacy and safety of three doses of the integrin inhibitor cilengitide compared with docetaxel in patients with stage IV non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. Journal of Thoracic Oncology. 4(9). 1 indexed citations
7.
Scagliotti, Giorgio V., Thomas Brodowicz, Frances A. Shepherd, et al.. (2009). Pemetrexed is more effective in patients with nonsquamous non-small cell lung cancer (NSCLC) histology: an analysis of three large, randomized, phase III trials. Journal of Thoracic Oncology. 4(9). 3 indexed citations
8.
Gridelli, Cesare, Andrea Ardizzoni, Jean‐Yves Douillard, et al.. (2009). Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 68(3). 319–331. 57 indexed citations
9.
Manegold, Christian, Gerald Schmid‐Bindert, & Lothar R. Pilz. (2009). Pemetrexed for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy. 9(9). 1195–1209. 11 indexed citations
10.
Scagliotti, Giorgio V., Purvish Parikh, Joachim von Pawel, et al.. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(21). 3543–3551. 2487 indexed citations breakdown →
11.
Nackaerts, Kristiaan, Corey J. Langer, Peter Harper, et al.. (2008). International Consensus Panel Recommendations for the diagnosis of bone metastases (METS) from lung cancer (LC). Journal of Thoracic Oncology. 3(4). 4 indexed citations
12.
13.
Zhong, Wen‐Zhao, Xue‐Ning Yang, Jianling Bai, et al.. (2008). Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery. 34(1). 187–195. 50 indexed citations
14.
Manegold, Christian, Armando Santoro, Mary O’Brien, et al.. (2007). C5-01: Open-label study of pemetrexed alone or in combination with a platinum in chemonaïve patients (pts) with malignant pleural mesothelioma (MPM): Results from the International Expanded Access Program (EAP). Journal of Thoracic Oncology. 2(8). S371–S371. 2 indexed citations
15.
16.
Reck, Martin, Joachim von Pawel, Petr Zatloukal, et al.. (2007). C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S360–S361. 6 indexed citations
17.
Bell, Daphne W., Thomas J. Lynch, Sara M. Haserlat, et al.. (2005). Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal of Clinical Oncology. 23(31). 8081–8092. 518 indexed citations breakdown →
18.
Scagliotti, Giorgio V., Hedy L. Kindler, Michael J. Vasconcelles, et al.. (2003). Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 21(8). 1556–1561. 200 indexed citations
19.
Manegold, Christian. (2002). Chemotherapy for advanced non-small cell lung cancer (NSCLC). Lung Cancer. 38. 47–50. 3 indexed citations
20.
Latz, D., Tobias Schulze, Christian Manegold, et al.. (1998). Combined effects of ionizing radiation and 4-hydroperoxyifosfamide in vitro. Radiotherapy and Oncology. 46(3). 279–283. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by U. Gatzemeier Breakdown of academic impact, for papers by Rodryg Ramlau Breakdown of academic impact, for papers by Vera Hirsh Breakdown of academic impact, for papers by Filippo de Marinis Breakdown of academic impact, for papers by Maciej Krzakowski Breakdown of academic impact, for papers by Isamu Okamoto Breakdown of academic impact, for papers by Camelia S. Sima Breakdown of academic impact, for papers by Frank V. Fossella Breakdown of academic impact, for papers by Nobuyuki Yamamoto Breakdown of academic impact, for papers by Tudor–Eliade Ciuleanu
Rankless by CCL
2026